Biocon Partner Duopharma Biotech Secures Insulin Tenders Worth Over MYR 225 Million in Malaysia
Biocon Limited announced that its partner, Duopharma Biotech Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million for the current year. This significant deal reinforces Biocon’s commitment to diabetes care in Malaysia through its wholly-owned subsidiary, Duopharma (M) Sendirian Berhad.Through this partnership, Biocon Sdn. Bhd., Malaysia will supply short-acting recombinant human insulin, insulin glargine, and insulin aspart for distribution by the local partner. These supplies aim to support continuous access to cost-effective, high-quality insulin therapies for people...